)
)
ABIVAX Investor Relations Material
Latest events
H2 2023
ABIVAX
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from ABIVAX Société Anonyme
Access all reports
ABIVAX Société Anonyme is a clinical-stage biotechnology company that focuses on developing therapeutics designed to modulate the body's natural immune regulatory mechanisms. The company is primarily engaged in advancing its lead drug candidate, obefazimod, which is currently undergoing clinical trials aimed at treating moderately to severely active ulcerative colitis. Additionally, ABIVAX is exploring obefazimod's potential in treating other chronic inflammatory diseases, including Crohn's disease, through ongoing clinical trials and research initiatives. The company is headquartered in Paris, France, and its shares are listed on both the Nasdaq and the Euronext Paris.
Key slides for ABIVAX Société Anonyme
Corporate Presentation
ABIVAX Société Anonyme
Corporate Presentation
ABIVAX Société Anonyme
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
ABVX
Country
🇫🇷 France